Brazil's health regulatory agency, Anvisa, has officially authorized the use of Mounjaro (tirzepatide) for pediatric patients. This decision expands treatment options for adolescents aged 10 and older diagnosed with type 2 diabetes in the country, marking a significant development in pediatric endocrinology care within Brazil.
The U.S. Food and Drug Administration has launched proof-of-concept clinical trials utilizing real-time data reporting. This initiative aims to modernize the drug development process, reduce timelines, and improve the efficiency of bringing new, safe, and effective medical treatments to patients in the United States.
President Donald Trump announced a deal with pharmaceutical company Regeneron to reduce the costs of its drug treatments for Medicaid and other federal programs. The agreement is part of broader efforts by the administration to address rising prescription drug prices in the United States and expand access to affordable healthcare options for patients.
Hungarian opposition leader Péter Magyar has announced plans to reclaim state-held shares in major corporations, including Mol Nyrt. and Gedeon Richter Nyrt., currently managed by academic foundations. The proposal aims to return these assets to state control, sparking debate over the governance and management of these significant national economic interests.
Pharmaceutical giants AbbVie and Genentech have joined the White House's TrumpRx initiative, a platform designed to provide Americans with access to discounted prescription medications. This expansion marks a significant development in the administration's efforts to address drug pricing through the digital portal.
Austria has aligned with four other European Union member states to advocate for a bloc-wide windfall tax on energy companies. The proposal aims to mitigate the impact of surging fuel and electricity prices on consumers and businesses by capturing excess profits generated by energy firms during the current market volatility.
The Australian government is assessing the potential impact of new US trade policies, which include a 100 percent tariff on specific pharmaceutical imports. Officials are working to ensure the stability of the Pharmaceutical Benefits Scheme (PBS) and maintain affordable access to essential medicines for all Australians amid shifting international trade dynamics.
The U.S. Food and Drug Administration has granted approval to Eli Lilly for Foundayo, a new once-daily oral GLP-1 receptor agonist designed for chronic weight management. This approval marks a significant expansion in the treatment options available for adults struggling with obesity or overweight conditions, offering an alternative to existing injectable therapies.
The U.S. Food and Drug Administration has granted approval for Foundayo, a new once-daily oral GLP-1 receptor agonist developed by Eli Lilly for chronic weight management. This milestone marks a significant expansion in non-injectable treatment options for patients struggling with obesity and weight-related health conditions in the United States.
The National Health Insurance Authority (NHIA) of Nigeria has entered a strategic partnership with Roche to improve access to essential medicines and specialized care. This collaboration aims to reduce out-of-pocket expenses for patients, particularly those requiring treatment for cancer and other chronic conditions, by integrating innovative therapies into the national health insurance framework.
Pharmaceutical giant Novartis has pledged 1.8 billion yuan to expand its Shanghai headquarters. This strategic investment aims to strengthen the company's research and development capabilities and operational footprint in China, reflecting a broader trend of multinational pharmaceutical firms increasing their presence in the Chinese market.
Chinese Commerce Minister Wang Wentao has assured executives from multinational pharmaceutical companies that China is committed to strengthening intellectual property protections and enhancing policy transparency to foster a better business environment for foreign investment.
Omeros Corporation is set to host an industry session focused on medical advancements at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Madrid, Spain. The session will highlight the company's ongoing research and clinical developments within the field of transplantation and hematology.
The U.S. Food and Drug Administration has released draft guidance aimed at helping drug developers validate non-animal testing methodologies. This initiative supports the agency's ongoing efforts to modernize drug development, reduce reliance on animal models, and promote the adoption of innovative, scientifically sound alternatives in the pharmaceutical industry.
A two-day industry meeting has commenced in Moscow, bringing together representatives from India and the Russian Federation to enhance bilateral trade and deepen cooperation within the pharmaceutical sector. The discussions aim to address supply chain resilience and explore new opportunities for joint ventures in drug manufacturing and research.
Health ministers from Russia and Egypt held high-level talks in Moscow to bolster bilateral ties in the medical and pharmaceutical sectors. The discussions focused on expanding collaboration in drug production, medical technology, and public health initiatives to enhance healthcare accessibility in both nations.
The U.S. Food and Drug Administration has introduced a new, unified platform designed to modernize the reporting and monitoring of adverse events for regulated products. This initiative aims to streamline data collection, improve safety surveillance, and enhance the agency's ability to identify and respond to potential health risks associated with FDA-regulated items.
The Irish Fiscal Advisory Council (IFAC) has reported that three multinational companies contributed 46% of Ireland's corporate tax in 2024, amounting to approximately €13 billion. This highlights the country's increasing reliance on a small number of firms for a significant portion of its public revenue, raising concerns about fiscal stability.
A significant majority of UK pharmacies, particularly in England, are reportedly at risk of imminent closure due to severe financial pressures. Industry bodies warn that underfunding, rising costs, and a reliance on personal savings are jeopardizing essential patient services.
Arrotex Pharmaceuticals and Pfizer Australia have forged a new strategic commercial partnership for the distribution of ENBREL (etanercept) across Australian pharmacy channels, effective February 1, 2026. This collaboration aims to enhance access to the biologic therapy for autoimmune conditions.
